BioNTech SE - ADR Stock

$111.00

1.59% today

Nasdaq, Aug 12, 10:00 pm CET

ISIN

US09075V1026

Symbol

BNTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

BioNTech SE - ADR Stock price

$109.26

+41.71 61.76% 5Y

Nasdaq, Closing price Mon, Aug 11 2025

-2.40 2.15%

ISIN

US09075V1026

Symbol

BNTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$26.8b

Enterprise Value

$7.6b

Net debt

positive

Cash

$19.5b

Shares outstanding

240.0m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

8.4 | 11.5

EV/Sales

2.4 | 3.3

EV/FCF

negative

P/B

1.2

Dividends

DPS

$0.00

Yield 1Y | 5Y

0.0% | 0.0%

Growth 1Y | 5Y

- | -

Payout 1Y | 3Y

0.0% | 0.0%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$3.2b | $2.3b

EBITDA

$-1,000.0m | $-2.0b

EBIT

$-1.3b | $-2.1b

Net Income

$-772.9m | $-1.5b

Free Cash Flow

$-284.2m

Growth (TTM | estimate)

Revenue

-28.0% | -26.8%

EBITDA

-181.5% | -95.8%

EBIT

-232.8% | -57.9%

Net Income

-171.5% | -91.1%

Free Cash Flow

-105.2%

Financial Health

Equity Ratio

86.2%

Return on Equity

-3.4%

ROCE

-5.8%

ROIC

-34.9%

Debt/Equity

0.0

EPS

$-3.3

FCF per Share

$-1.2

Short interest

6.5%

Employees

Rev per Employee

$470.0k

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Get Started for Free Today

BioNTech SE - ADR Stock Analysis

Unlock Scores for Free

??

27 Analysts have issued a BioNTech SE - ADR forecast:

20x Buy

74%

7x Hold

26%

More details on Analyst Estimates Including Price Targets

27 Analysts have issued a BioNTech SE - ADR forecast:

Buy

74%

Hold

26%

Analyst Estimates with Stock Price Targets

Financial data from BioNTech SE - ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	3,196 3,196	28% 28% 100%
- Direct Costs	483 483	31% 31% 15%
Gross Profit	2,713 2,713	27% 27% 85%
- Selling and Administrative Expenses	696 696	7% 7% 22%
- Research and Development Expense	2,619 2,619	30% 30% 82%
EBITDA	-1,000 -1,000	182% 182% -31%
- Depreciation and Amortization	346 346	62% 62% 11%
EBIT (Operating Income) EBIT	-1,346 -1,346	233% 233% -42%
Net Profit	-773 -773	172% 172% -24%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

BioNTech SE - ADR Stock News

Positive

Reuters

●

5 days ago

CureVac settles patent dispute litigation with Pfizer and BioNTech

CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and BioNTech related to mRNA-based COVID-19 vaccines.

Neutral

Seeking Alpha

●

8 days ago

BioNTech SE (BNTX) Q2 2025 Earnings Call Transcript

BioNTech SE (NASDAQ:BNTX ) Q2 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Douglas Maffei - Investor Relations Ozlem Tureci - Co-Founder, Chief Medical Officer & Member of Management Board Ramón Zapata-Gomez - CFO & Member of Management Board Ryan Richardson - Chief Strategy Officer, MD & Member of Management Board Ugur Sahin - Co-Founder, CEO & Chair of the Mana...

Positive

Barrons

●

8 days ago

BioNTech Stock Rises as Drug Maker Beats Earnings Expectations.

The drug maker reported a narrower-than-expected loss in the second quarter.

More BioNTech SE - ADR News

Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 for prostate cancer; BNT113 that is in Phase I clinical trial to treat HPV+ head and neck cancers; BNT114, which is in Phase I clinical trial for triple negative breast cancer; and BNT115 and BNT116 to treat other cancers, including ovarian cancer. It also develops individualized neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; next-generation checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has a collaboration with Pfizer Inc. to develop vaccines for the coronavirus using its mRNA-based drug development platform; and development and commercialization collaboration with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. to advance a vaccine candidate BNT162 for the prevention of COVID-19 infections. The company was founded in 2008 and is headquartered in Mainz, Germany.

Head office	Germany
CEO	Ugur Sahin
Employees	6,772
Founded	2008
Website	www.biontech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now